INNOVENT BIO (01801) Strategic Collaboration with Eli Lilly Takes Effect, Company Clarifies It Is Not an Acquisition

Stock News03-25 07:47

INNOVENT BIO (01801) has announced that all preconditions for the strategic collaboration agreement with Eli Lilly, initially disclosed on February 8, 2026, to advance new drug development in oncology and immunology, have now been satisfied. The company has received early termination of the waiting period under the Hart-Scott-Rodino Act. Consequently, the strategic collaboration agreement became effective on March 24, 2026, Hong Kong time. The company noted that some media reports have mistakenly interpreted the agreement's effectiveness as an acquisition of the company. INNOVENT BIO hereby clarifies that it has not, and has no intention to, engage in such a transaction. Shareholders and potential investors are advised not to rely on market rumors concerning the group. Any information about the group should be sourced solely from the company's official announcements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment